Abstract
Objective: To assess the prognostic significance of angiogenesis parameters such as microvessel density (MVD) and vascular endothelial growth factor (VEGF) in superficial bladder cancer. Patients and methods: We studied 127 superficial bladder cancer samples immunohistochemically for the above factors. We compared them with standard clinicopathological features (grade, stage, concurrent in situ, multifocality, primary or recurrent status) as well as with p53 expression, recurrence and progression to muscle infiltrating disease. Results: During a 36 months median follow up of 109 patients with superficial primary tumors (min. 3, max. 69 months), 80 of them recurred (73.4%), while 8 patients (7.3%) progressed to muscle invading disease. A significant correlation was noted between MVD and VEGF in all 127 samples (p = 0.019). No association was noted between MVD or VEGF with the other clinicopathological features, recurrence or progression. Although progression free survival rates of categorized microvessel density (up to and higher than median value) differed significantly only in grade 3 patients, no independent prognostic significance could be attributed to MVD. No correlation was observed between MVD or VEGF with p53 protein. Conclusions: Based on our data we suggest that VEGF is not useful for predicting recurrence or progression in superficial bladder cancer. Microvessel density determination may help to predict progression of grade 3 patients to muscle invasive disease but not as an independent prognostic factor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Landis SH, Murray T, Borden S. Cancer statistics. CA Cancer J Clin 1999: 49: 8.
Cheng L, Weaver A, Neumann RM et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999; 86: 1035.
Bane BL, Rao JY, Hemstreet GP. Pathology and staging of bladder cancer. Sem Oncol 1996; 23: 546–570.
Lutzeyer W, Rubben H, Dahn H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127: 250.
Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762–766.
Bochner BH, Cote RJ, Weider N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87: 1603–1612.
Dinney CP, Babkowski RC, Antelo M et al. Relationship among cystectomy, microvessel density and prognostic stage T1 transitional cell carcinoma of the bladder. J Urol 1998; 160(4): 1285–1290.
Brown LF, Berse B, Jackman RW et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Path 1993; 143(5): 1255–1262.
Leung DW, Cachianes G, Kuana WJ, Goeddal DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246(4935): 1306–1309.
Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris A. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999; 161: 799–804.
Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259–1264.
Spissl B, Beahrs O, Hermanek P et al. TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors (UICC edn). Berling: Springer Verlag, 1992.
Philp EA, Stephenson TJ, Reed MW. Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder. Br J Urol 1996; 77(3): 352–357.
Chandhary R, Bromley M, Clarke NW et al. Prognostic relevance of microvessel density in cancer of the urinary bladder. Anticancer Res 1999; (4)C: 3479–3484.
Babkowski RC, Zhang H, Xia WY et al. Angiogenesis does not have prognostic value in T1 bladder cancer. J Urol 1996; 155–615A.
Crew JP, O'Brien T, Bradburn M et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57(23): 5281–5285.
Chow NH, Liu HS, Chan SH, Cheng HL, Tzai TS. Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res 1999; 19(5C): 4593–4597.
Ogura Y, Sato K, Kato T, Saito K, Enomoto K. Immunohistochemical analysis of expression of angiogenic factors and tumors angiogenesis in superficial bladder cancer. Nippon Hinyokika Gakkai Zasshi 1998; 89(5): 529–537.
Reiher F, Ozer O, Pins M et al. P53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002; 167: 1469–1474.
Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135.
Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Nat Cancer Inst 1997; 89(3): 219–227.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stavropoulos, N.E., Bouropoulos, C., Ioachim, I.E. et al. Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 36, 163–167 (2004). https://doi.org/10.1023/B:UROL.0000034676.50636.e0
Issue Date:
DOI: https://doi.org/10.1023/B:UROL.0000034676.50636.e0